BIIB vs. BMY
Compare and contrast key facts about Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIIB or BMY.
Key characteristics
| BIIB | BMY | |
|---|---|---|
| YTD Return | -23.95% | -3.25% |
| 1Y Return | -31.70% | -28.19% |
| 3Y Return (Ann) | -10.08% | -6.33% |
| 5Y Return (Ann) | -2.84% | 4.62% |
| 10Y Return (Ann) | -3.03% | 2.85% |
| Sharpe Ratio | -1.40 | -1.43 |
| Daily Std Dev | 22.99% | 19.92% |
| Max Drawdown | -90.00% | -70.62% |
| Current Drawdown | -55.11% | -36.63% |
Fundamentals
| BIIB | BMY | |
|---|---|---|
| Market Cap | $31.34B | $109.66B |
| EPS | $7.98 | $3.86 |
| PE Ratio | 27.02 | 14.05 |
| PEG Ratio | 6.24 | 2.46 |
| Revenue (TTM) | $9.84B | $45.01B |
| Gross Profit (TTM) | $7.90B | $36.38B |
| EBITDA (TTM) | $2.38B | $18.42B |
Correlation
The correlation between BIIB and BMY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
BIIB vs. BMY - Performance Comparison
In the year-to-date period, BIIB achieves a -23.95% return, which is significantly lower than BMY's -3.25% return. Over the past 10 years, BIIB has underperformed BMY with an annualized return of -3.03%, while BMY has yielded a comparatively higher 2.85% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BIIB vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIIB vs. BMY - Dividend Comparison
BIIB has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.82%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.82% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
BIIB vs. BMY - Drawdown Comparison
The maximum BIIB drawdown since its inception was -90.00%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for BIIB and BMY. For additional features, visit the drawdowns tool.
Volatility
BIIB vs. BMY - Volatility Comparison
Biogen Inc. (BIIB) has a higher volatility of 6.10% compared to Bristol-Myers Squibb Company (BMY) at 5.62%. This indicates that BIIB's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.